Regulatory Support for Tobacco Products. Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help.

Similar documents
BATTELLE CANCER RESEARCH INITIATIVE. Bridging the Gap between Discovery and Application

ELECTRONIC CIGARETTES WHAT S THE BOTTOM LINE?

RE: Docket No. FDA-2014-N , Electronic Cigarettes and the Public Health

UPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP)

UPDATE ON PREMARKET TOBACCO PRODUCT AUTHORIZATION PATHWAY

Addressing the Challenge of ENDS Regulation. David Graham President & Managing Partner Reveritas Group

UNITED STATES REGULATION OF TOBACCO PRODUCTS. Presented by Mitch Zeller Center Director FDA Center for Tobacco Products

Modelling the effects of user exposure to harmful emissions across the spectrum of nicotine delivery

FDLI s Enforcement, Litigation, and Compliance Conference. Center for Tobacco Products Office of Compliance and Enforcement 2017 Update

Responsible Practice in E-Vapour Products (EVP) Product Stewardship

FDA Center for Tobacco Products: Tobacco Research and the Population Assessment of Tobacco and Health (PATH) Study

FEATURES AND PERFORMANCE OF THE HPP SMOKING MACHINE. Dritan Xhillari

TOBACCO PRODUCT OR MEDICAL PRODUCT?

Global E-Cigarette Market- Industry Analysis & Outlook ( )

Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Products

Peter G. Shields, MD Tobacco Products Scientific Advisory Committee (TPSAC) August 16, 2013

FORMs of TOBACCO. 2 nd of 3 Prep for Session 1

Sacramento City College Smoke/Tobacco/Vape (STV) Free Environmental Standard

How to Regulate E-Cigarettes? Are we asking the right questions?

FDA s Action Agenda to Reduce Tobacco Related-Cancer Incidence and Mortality

E-Cigarettes & Vaping. Information for Women & Their Families

FDLI Tobacco Products Regulation and Policy Conference Joe Murillo Vice President, Regulatory Affairs October 27, 2017

DECISION. Recalling further its decision FCTC/COP5(6) to adopt further partial guidelines;

JUUL and Other Emerging Tobacco Products. Emily McClelland, M.S. December 6, 2018

Should FDA try to move smokers to e-cigarettes or other less harmful tobacco-nicotine products and, if so, how?

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

6/2/2015. Welcome to VAPE U! Module V: Legal Challenges in the E-Liquid Market

National Conference of State Legislatures Legislative Summit: Clearing the Air About E-Cigarettes

The Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j))

Electronic Cigarettes, Nicotine and Policy Implications

Heat-not-Burn Products: Scientific Assessment of Risk Reduction

The Legal Resource Center for Public Health Policy provides information and technical assistance on issues related to public health in Maryland.

Assessment of the Tobacco Heating System (THS) 2.2, A Candidate Modified Risk Tobacco Product: From Concept to Early Clinical Data

CAMPUS SMOKING POLICY

Tobacco-related risk perceptions in the regulation of tobacco products at the FDA Center for Tobacco Products

Communicating the Risk of Nicotine Delivery Products

E-Cigarette Update: Secondhand Vapour

Planning For The FDA s 'Deeming Rule' For E- Cigarettes

Modified Risk Tobacco Product Applications A Succinct ENDS Industry Perspective

The importance of offering adult smokers a portfolio of potentially less harmful products

FDLI Annual Conference

Advanced in vitro exposure systems VITROCELL VC 1 SMOKING MACHINE

E-Cigarettes and Vapes

A proposed bridging approach for the assessment of novel tobacco products

Boehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence

AN UPDATE ON FDA S COMPREHENSIVE PLAN ON TOBACCO AND NICOTINE

Pierre-Marie GUITTON Next Generation Nicotine Delivery London June, 2017

Safety/risk assessment of electronic cigarettes

DRAFT FOR COMMENT ( ) All Tobacco Products are Deadly and Addictive: Product Diversity Challenges Regulation and Communication

FDA S CENTER FOR TOBACCO PRODUCTS: AN UPDATE ON REGULATORY ACTIVITIES AND PRIORITIES

MDQuit Best Practices Conference January 26, Presented by William C. Tilburg Deputy Director

Advanced in vitro exposure systems

HOW TO: Collect Information Required For The FDA s E-Liquid and E-Vapor Device Ingredient Listing Reports

Recent Advances In Tobacco Science

NYS Conference of Environmental Health Directors Meeting October 28, 2014

00:08 For decades our scientists have endeavoured to reduce the risks of tobacco use and continue to do so today. 00:15

MODIFIED RISK TOBACCO PRODUCT MARKETING DECISIONS

Texas Bill to Regulate Vapor Products. Over the past few years, electronic cigarettes, also commonly referred to as e-cigarettes

Nicotine delivery from e-cigarettes part I: study designs for two pharmacokinetic studies.

AHEC Tobacco Online Modules

Contribution To Standards Development For Next Generation Products. Eduardo BEREA Alternative Ingredients ENDS 2018 London 4-5 June 2018

Air Quality assessment during indoor use of the Tobacco Heating System 2.2

A combination of licensed medication and professional support is four times more likely to achieve a stop in smoking behaviour.

CHARACTERIZATION OF PUFF TOPOGRAPHY DURING 8- HOURS OF AD LIBITUM USE OF MARKTEN E-VAPOR PRODUCTS

My story parallels many of my own customers. I smoked for nearly 20 years, beginning in college, a combination of factors contributing to my

Electronic Nicotine Delivery Systems

Contribution To Standards Development For Next Generation Products. Dr Nils ROSE

Tobacco Cessation, E- Cigarettes and Hookahs

E-Cigs, Etc.: Policy Options for Regulating Nicotine Delivery Devices. Indiana Local Boards of Health Webinar Feb. 12, 2015

Electronic Cigarettes and the Medical Society

E-cigarette consumption and puffing topography data. Dr Sudhanshu Patwardhan FDA CTP Workshop, Hyattsville, Maryland. March 9, 2015.

The concept that not all tobacco and nicotine products

Innovator in Chelated Mineral Nutrition

Mitch Zeller, Director, Center for Tobacco Products, FDA September 19, 2013 Kansas Public Health Association

Stop the Vape. Maria Hines RN, MSN. Denise Kneubuhler RN, MSN

Smoking, e-cigs and reduced risk products. Dr John Schoonbee, IMS November 2017

REQUEST FOR COUNCIL ACTION

ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE

Components of a Successful Policy

Coach on Call. Thank you for your interest in E-Cigarettes: Your Questions Answered. I hope you find this tip sheet helpful.

Analysis of the Public's Perception on the Use of E- Cigarettes as an Alternative to Smoking

Medpace, a pioneer in the development of therapeutics to treat metabolic disorders, is your first stop for compound development in lipid studies.

Because PMI application did not report the full range of HPHCs in IQOS aerosol,

UK E-Cigarette Summit Relative risks of cancer posed by combustible and vapourising forms of nicotine delivery: Evidence from chemical exposures

Tobacco Data, Prevention Spending, and the Toll of Tobacco Use in North Carolina

Is Vaping a Valid Strategy for Smoking Cessation? Myths and Facts Jaspreet S. Brar. MD, PhD Community Care Behavioral Health Organization

V2 NOTEBOOK-CIG AND/OR V2 POWER-CIG

CATCH MY BREATH. ASHA Conference: October 12, Marcella Bianco CATCH My Breath Program Manager CATCH Global Foundation

EMBASE Find quick, relevant answers to your biomedical questions

PSYCHIATRY. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Psychiatry. Scientifically-Driven Clinical Development

E-Cigarettes: A Game Changer. Dr. Blake Brown Hugh C. Kiger Professor Agriculture and Resource Economics College of Agriculture & Life Sciences

Abt Associates Inc. Immunization and Health Services Research Helping our clients address critical health issues around the world

E-Cigarette Product Regulation and Standardisation

Boehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider

NAVIFY Tumor Board NAVIFY

PRODUCT CATALOG. VAPOR4LIFE INC. Advanced Vaping Technology

Kevin Walton, Ph.D. Chief, Clinical Research Grants Branch Division of Therapeutics and Medical Consequences NIDA. No disclosures

MARKETING STANDARDS FOR MEMBERSHIP

Product Information for Labs. etkon ident Perfectly versatile. Performance you can rely on.

Transcription:

Regulatory Support for Tobacco Products Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help.

PREMARKET TOBACCO (PMTA) HUMAN FACTORS STUDIES SUBSTANTIAL EQUIVALENCE (SE) OUR SERVICES MODIFIED RISK TOBACCO PRODUCT (MRTP) PRECLINICAL AND CLINICAL STUDIES INVESTIGATIONAL TOBACCO PRODUCT (ITP)

At Battelle, we ve been studying tobacco and nicotine products for more than 50 years and have a deep understanding of Food and Drug Administration (FDA) regulatory requirements. Our experienced team can help you navigate the regulatory process with confidence and find the fastest (and most economical) path to market approval. The Smoothest Path to Approval Starts at Battelle. Expert Guidance to Streamline Project Timelines Battelle does more than just conduct standard studies. We provide comprehensive services for tobacco product manufacturers to guide you at every step along the way to market approval. From data collection to application submission, our team will make sure you fully understand the FDA s compliance policies, application requirements and timelines so you can make informed, strategic decisions.

Trusted Results, from the Lab to Clinical Studies Battelle has operated at the forefront of nicotine and tobacco research for decades. Our research experience spans the full range of tobacco products available, including cigarettes, cigars, smokeless tobacco, waterpipes, electronic cigarettes (e-cigarettes), many other types of Electronic Nicotine Delivery Systems (ENDS), heated tobacco cigarettes and other products. Battelle brings together experts from a broad range of disciplines including chemistry, bioinformatics, economics, engineering, mathematics, medicine, psychology, pharmacology, statistics and toxicology to provide highquality, defensible data and to find novel solutions for out-of-the-ordinary research challenges. The Battelle team brings together expertise in preclinical and clinical tobacco research, human factors studies, analytics and product engineering to analyze your product and help you find the fastest path to market approval. We are uniquely positioned to provide expert guidance on how to bridge and leverage published data to develop the case for premarket tobacco applications (PMTA), minimizing the need for new clinical data collection. Our approach helps clients reduce project timelines and prioritize research efforts where primary data collection is required.

Science to Support Tobacco Product Applications Battelle offers a full suite of analytical, preclinical and clinical services to support the regulatory process. Our study directors and staff have extensive experience in designing and conducting studies required for market approval. Literature Analysis to Support Bridging and Premarket Tobacco Applications We use advanced analytical methods to scan the available literature for published studies that provide evidence for Premarket Tobacco Applications (PMTA). The algorithm automatically extracts and represents the knowledge contained in scientific, technical or general text in a form that enables complex query and knowledge discovery/visualization. This allows us to streamline the process of finding and leveraging data for a PMTA and discover connections hiding in large bodies of published studies. Product Characterization and Analyses We apply, develop and validate regulatory-compliant chemical measurement methods to characterize product components, ingredients, additives and flavors. Our staff conduct highly accurate and reliable chemical analysis for precise measurement of volatile and semi-volatile organic compounds (VOCs/SVOCs), heavy metals, particulates and tobacco-specific nitrosamines in complex mixtures, including vapors and aerosols. Toxicology Studies The Battelle Inhalation Toxicology Center has the expertise and experience you need to move products through the regulatory process quickly and efficiently. We are among the largest specialized in vivo laboratories in the United States, with more than 30 years of experience conducting specialized inhalation toxicology studies for government and commercial clients in the pharmaceutical, agricultural, chemical and tobacco industries. We provide accurate, objective data for preclinical toxicology studies under regulatory-compliant (FDA) guidelines. Preclinical and Clinical Participant Studies For decades, we have operated at the forefront of nicotine and tobacco research. We conduct both preclinical and clinical participant studies at our specialized facilities to collect data on user behavior, abuse liability, nonclinical health risk, human health impact and biomarkers of exposure. Our studies are designed to help you understand how product characteristics, user behavior and exposure interrelate so you can make informed decisions and gather the data you need to support market approval. Human Factors Studies We can help you understand pre-market evaluation and post-market activities. Our human factors team will guide you on how product design and labeling impact user behaviors, including initiation, cessation and dual use, as well as consumer perceptions and risks.

Our Facilities Our tobacco product research is conducted in state-ofthe-art facilities in Baltimore, MD, and Columbus, OH, that are compliant with Good Laboratory Practice (GLP) and Good Clinical Practice (GCP). We have unique experimental chambers designed to safely test tobacco products and rigorously assess environmental exposure. Our facilities house some of the most sophisticated analytical equipment in the world, including puff topography systems, laboratory-based smoking machine devices and breath analyzers for highly accurate quantitative data collection. Our facilities include: Preclinical facilities at a state-of-the-art toxicology center with leading experts in inhalation study design to deliver end-to-end solutions Clinical laboratories with specially ventilated air circulation systems, allowing for vaping and combustible product smoking indoors Bench laboratories utilizing state-of-the-art organic and inorganic analytical instruments and innovative characterization technologies Environmental exposure chambers that offer a contaminant-free environment Human factors laboratory where experts conduct usability analysis, cognitive psychology and product design research. Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Headquartered in Columbus, Ohio since its founding in 1929, Battelle serves the national security, health and life sciences, and energy and environmental industries. For more information, visit www.battelle.org. 800.201.2011 ú solutions@battelle.org ú www.battelle.org Battelle and its logos are registered trademarks of Battelle Memorial Institute. Battelle Memorial Institute 2017. All Rights Reserved. ID 586 04/17